LumiraDx (LMDX) Set to Announce Earnings on Tuesday

LumiraDx (NASDAQ:LMDX – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, March 21st. Analysts expect LumiraDx to post earnings of ($0.19) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

LumiraDx Trading Up 3.7 %

LMDX stock opened at $0.90 on Friday. The company has a current ratio of 2.91, a quick ratio of 1.63 and a debt-to-equity ratio of 20.12. LumiraDx has a 1 year low of $0.77 and a 1 year high of $8.93. The stock has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.09.

Institutional Trading of LumiraDx

Hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management LLC grew its holdings in shares of LumiraDx by 36,072.9% during the third quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company’s stock valued at $3,847,000 after buying an additional 3,760,959 shares in the last quarter. Colony Group LLC acquired a new position in shares of LumiraDx during the 2nd quarter worth about $787,000. Renaissance Technologies LLC acquired a new position in shares of LumiraDx during the 3rd quarter worth about $50,000. Pathstone Family Office LLC bought a new position in LumiraDx during the third quarter valued at about $47,000. Finally, Citadel Advisors LLC bought a new position in LumiraDx during the third quarter valued at about $39,000.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group began coverage on LumiraDx in a research note on Monday, December 19th. They set a “neutral” rating for the company.

About LumiraDx

(Get Rating)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.